D. Boral Capital initiated coverage of Avita Medical (RCEL) with a buy score and $25 target price Avita’s Recell technology has shown “promising results” in clinical trials for a variety of skin and soft tissue indications and Avita is “poised for significant growth” from expanding penetration of the market in traumatic wounds, surgical wounds and “slowly but surely chronic wounds”. “As awareness of the technology increases and adoption grows in hospitals and burn centers around the world, the analyst tells investors.

First published in The Fly – the ultimate source of real-time, breaking financial news that moves the market. Try now >>

Check out the best stocks recommended by analysts >>

Read more about RCEL: